Dissolvable microneedle patches that deliver the flu vaccine could provide a safe and cost-effective alternative to traditional immunization methods, according to the results from a Phase I trial published in The Lancet this week.
The study enrolled adults ages 18 to 49 and randomly assigned them to receive a single dose of inactivated flu vaccine via microneedle patch, intramuscular injection or a placebo by microneedle patch – all administered by a healthcare practitioner. The 4th group self-administered an inactivated flu vaccine using a microneedle patch.
Get the full story at our sister site, Drug Delivery Business News.
The post Dissolvable microneedle patch for flu vaccine succeeds in Phase I appeared first on MassDevice.